Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BACH: PLD vs Doxorubicin in HER2+ Breast Cancer
NCT00550771Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2007
- Primary completion
- Aug 2010
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 2, randomised, open-label trial of pegylated liposomal doxorubicin in breast cancer (2 arms), sponsored by Merck & Co. Primary endpoint: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total… at 1 year. Started Jul 2007; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00550771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550771.